top of page

New oral treatment for rheumatoid arthritis

The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Olumiant (baricitinib) for the treatment of adults with moderate to severe active rheumatoid arthritis.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page